董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Andrew Gengos | 男 | Independent Director | 62 | 10.00万美元 | 61.39 | 2026-11-30 |
| Bradley Burnam | 男 | Chief Executive Officer and Director | 48 | 65.20万美元 | 1511.63 | 2026-11-30 |
| Neil Ghodadra | 男 | Chief Medical Officer and Director | 47 | 10.00万美元 | 101.00 | 2026-11-30 |
| Kent Kester | 男 | Independent Director | 66 | 10.00万美元 | 13.34 | 2026-11-30 |
| Arthur Golden | 男 | Independent Director | 80 | 10.00万美元 | 106.02 | 2026-11-30 |
| Martin Dewhurst | 男 | Independent Director | 63 | 未披露 | 11.17 | 2026-11-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Zuraiz Chaudhary | 男 | Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer | 31 | 142.68万美元 | 25.25 | 2026-11-30 |
| Bradley Burnam | 男 | Chief Executive Officer and Director | 48 | 65.20万美元 | 1511.63 | 2026-11-30 |
| Neil Ghodadra | 男 | Chief Medical Officer and Director | 47 | 10.00万美元 | 101.00 | 2026-11-30 |
董事简历
中英对照 | 中文 | 英文- Andrew Gengos
-
Andrew Gengos，于2017年10月加入我们，担任首席运营官兼企业发展主管。Gengos先生最近于2012年12月至2016年12月担任ImmunoCellular Therapeutics（一家上市的免疫肿瘤学公司，致力于胶质母细胞瘤的治疗）的总裁，首席执行官兼董事。此前，Gengos从2010年2月到2012年8月担任Neuraltus Pharmaceuticals总裁和首席执行官。任职Neuraltus公司之前，Gengos先生曾在安进公司（Amgen）任职7年多，在那里，作为Vice President、战略和企业发展，他管理安进公司在全球范围内的内外业务开发活动，包括收购、许可、分拆、资产剥离、企业风险投资等一系列广泛的业务，其中包括董事会职位和联盟管理。此外，他曾领导战略项目的执行，并支持公司的长期规划过程。在加入Amgen之前，Gengos先生是Dynavax Technologies的Vice President、首席财务官和首席商务官，在那里他领导该公司的业务职能，包括财务和会计、筹资、预算和规划以及业务发展。在其职业生涯早期，Gengos先生曾担任Chiron Corporation的战略Vice President和麦肯锡公司的高级业务经理。Gengos先生拥有加州大学洛杉矶分校安德森管理学院（UCLA Anderson School of Management）工商管理硕士学位和麻省理工学院（Massachusetts Institute of Technology）化学工程学士学位。
Andrew Gengos has served as a director since January 2020. Since June 2026, Mr. Gengos has served as Chief Financial Officer for Immuneering Corporation where he manages finance, accounting, and investor relations. Prior to Immuneering Corporation, he served as Chief Financial Officer of Terns Pharmaceuticals, Inc. between March 2025 and May 2026 where he managed finance, accounting, and investor relations. Prior to Terns, he served as the Chief Financial Officer and Chief Business Officer at Athira Pharma between May 2023 and October 2024, where he managed finance, accounting, business development, corporate strategy, investor and public relations. Between January 2020 and February 2023, Mr. Gengos served as Chief Business Officer at Cytier Therapeutics, where he managed finance, accounting, business development, corporate strategy and IT. Mr. Gengos is a seasoned executive with over 30 years of experience in the life sciences and biotechnology industries, specializing in finance, corporate strategy, and business development. His earlier career includes serving as Vice President of Strategy and Corporate Development at Amgen and Senior Engagement Manager at McKinsey & Company where he was a member of the healthcare practice. Mr. Gengos has served as a director of Seneca Therapeutics since March 2025. Mr. Gengos holds a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology and a Master of Business Administration from the UCLA Anderson School of Management. - Andrew Gengos，于2017年10月加入我们，担任首席运营官兼企业发展主管。Gengos先生最近于2012年12月至2016年12月担任ImmunoCellular Therapeutics（一家上市的免疫肿瘤学公司，致力于胶质母细胞瘤的治疗）的总裁，首席执行官兼董事。此前，Gengos从2010年2月到2012年8月担任Neuraltus Pharmaceuticals总裁和首席执行官。任职Neuraltus公司之前，Gengos先生曾在安进公司（Amgen）任职7年多，在那里，作为Vice President、战略和企业发展，他管理安进公司在全球范围内的内外业务开发活动，包括收购、许可、分拆、资产剥离、企业风险投资等一系列广泛的业务，其中包括董事会职位和联盟管理。此外，他曾领导战略项目的执行，并支持公司的长期规划过程。在加入Amgen之前，Gengos先生是Dynavax Technologies的Vice President、首席财务官和首席商务官，在那里他领导该公司的业务职能，包括财务和会计、筹资、预算和规划以及业务发展。在其职业生涯早期，Gengos先生曾担任Chiron Corporation的战略Vice President和麦肯锡公司的高级业务经理。Gengos先生拥有加州大学洛杉矶分校安德森管理学院（UCLA Anderson School of Management）工商管理硕士学位和麻省理工学院（Massachusetts Institute of Technology）化学工程学士学位。
- Andrew Gengos has served as a director since January 2020. Since June 2026, Mr. Gengos has served as Chief Financial Officer for Immuneering Corporation where he manages finance, accounting, and investor relations. Prior to Immuneering Corporation, he served as Chief Financial Officer of Terns Pharmaceuticals, Inc. between March 2025 and May 2026 where he managed finance, accounting, and investor relations. Prior to Terns, he served as the Chief Financial Officer and Chief Business Officer at Athira Pharma between May 2023 and October 2024, where he managed finance, accounting, business development, corporate strategy, investor and public relations. Between January 2020 and February 2023, Mr. Gengos served as Chief Business Officer at Cytier Therapeutics, where he managed finance, accounting, business development, corporate strategy and IT. Mr. Gengos is a seasoned executive with over 30 years of experience in the life sciences and biotechnology industries, specializing in finance, corporate strategy, and business development. His earlier career includes serving as Vice President of Strategy and Corporate Development at Amgen and Senior Engagement Manager at McKinsey & Company where he was a member of the healthcare practice. Mr. Gengos has served as a director of Seneca Therapeutics since March 2025. Mr. Gengos holds a Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology and a Master of Business Administration from the UCLA Anderson School of Management.
- Bradley Burnam
-
Bradley Burnam自2018年10月起担任Global Health Solutions，Inc.首席执行官和董事。Burnam先生是一位创新者和企业家，在开发突破性的医疗保健解决方案方面有着良好的业绩记录。Burnam先生推动了变革性医疗产品的开发，并获得了三项FDA许可。他拥有10多项已发布的专利，体现了他在配方和创新方面的专长。他深厚的监管知识让alloGlobal Health Solutions，Inc.让他以顾问的身份独立驾驭FDA的批准流程。Burnam先生自2020年12月起担任Baropace，LLC的董事。Burnam先生拥有加州大学洛杉矶分校（“UCLA”）的文学学士学位和斯坦福大学的教育硕士学位。
Bradley Burnam has served as Chief Executive Officer and as a director since October 2018. Mr. Burnam is an innovator and entrepreneur with a proven track record in developing groundbreaking healthcare solutions. Mr. Burnam has driven the development of transformative medical products and achieved three FDA clearances. He holds over 10 issued patents, reflecting his expertise in formulation and innovation. His deep regulatory knowledge has allowed him to navigate FDA approval processes independently and as a consultant. Mr. Burnam has served as a director of Baropace, LLC since December 2020. Mr. Burnam holds a Bachelor of Arts from the University of California, Los Angeles ("UCLA") and a Master of Education from Stanford University. - Bradley Burnam自2018年10月起担任Global Health Solutions，Inc.首席执行官和董事。Burnam先生是一位创新者和企业家，在开发突破性的医疗保健解决方案方面有着良好的业绩记录。Burnam先生推动了变革性医疗产品的开发，并获得了三项FDA许可。他拥有10多项已发布的专利，体现了他在配方和创新方面的专长。他深厚的监管知识让alloGlobal Health Solutions，Inc.让他以顾问的身份独立驾驭FDA的批准流程。Burnam先生自2020年12月起担任Baropace，LLC的董事。Burnam先生拥有加州大学洛杉矶分校（“UCLA”）的文学学士学位和斯坦福大学的教育硕士学位。
- Bradley Burnam has served as Chief Executive Officer and as a director since October 2018. Mr. Burnam is an innovator and entrepreneur with a proven track record in developing groundbreaking healthcare solutions. Mr. Burnam has driven the development of transformative medical products and achieved three FDA clearances. He holds over 10 issued patents, reflecting his expertise in formulation and innovation. His deep regulatory knowledge has allowed him to navigate FDA approval processes independently and as a consultant. Mr. Burnam has served as a director of Baropace, LLC since December 2020. Mr. Burnam holds a Bachelor of Arts from the University of California, Los Angeles ("UCLA") and a Master of Education from Stanford University.
- Neil Ghodadra
-
Neilesh“Neil”Shailesh Ghodadra博士自2018年10月起担任Global Health Solutions，Inc.首席医疗官和董事。自2011年7月以来，Ghodadra博士一直担任Neil Ghodadra MD Inc.的总裁。Ghodadra博士是一名获得董事会认证的骨科外科医生，专门从事膝关节、肩关节、肘关节和髋关节的微创、关节镜手术。他在软骨修复和关节保持性截骨方面拥有广泛的专业知识，专注于不稳定和肩袖修复等复杂肩部疾病。Ghodadra博士拥有杜克大学的理学学士学位和杜克大学的医学博士学位。Ghodadra博士完成了在芝加哥RGlobal Health Solutions，Inc.h医疗中心的住院治疗，并获得了运动医学奖学金，在此期间，他曾担任芝加哥公牛和芝加哥白袜的副队医生。除了临床实践，他还向多家医疗公司咨询开发创新产品，借鉴了他在临床试验方面的长期经验。
Neil Ghodadra has served as Chief Medical Officer and a director since October 2018. Since July 2011, Dr. Ghodadra has served as the President of Neil Ghodadra MD Inc. Dr. Ghodadra is a board certified orthopedic surgeon specializing in minimally invasive, arthroscopic surgeries of the knee, shoulder, elbow and hip. He possesses extensive expertise in cartilage restoration and joint preserving osteotomies, focusing on complex shoulder conditions such as instability and rotator cuff repairs. Dr. Ghodadra holds a Bachelor of Science from Duke University and a Doctor of Medicine from Duke University. Dr. Ghodadra completed his residency at Rush Medical Center in Chicago and a Sports Medicine Fellowship, during which he served as an associate team physician for the Chicago Bulls and Chicago White Sox. Beyond his clinical practice, he consults with multiple medical companies to develop innovative products, drawing on his lengthy experience in clinical trials. - Neilesh“Neil”Shailesh Ghodadra博士自2018年10月起担任Global Health Solutions，Inc.首席医疗官和董事。自2011年7月以来，Ghodadra博士一直担任Neil Ghodadra MD Inc.的总裁。Ghodadra博士是一名获得董事会认证的骨科外科医生，专门从事膝关节、肩关节、肘关节和髋关节的微创、关节镜手术。他在软骨修复和关节保持性截骨方面拥有广泛的专业知识，专注于不稳定和肩袖修复等复杂肩部疾病。Ghodadra博士拥有杜克大学的理学学士学位和杜克大学的医学博士学位。Ghodadra博士完成了在芝加哥RGlobal Health Solutions，Inc.h医疗中心的住院治疗，并获得了运动医学奖学金，在此期间，他曾担任芝加哥公牛和芝加哥白袜的副队医生。除了临床实践，他还向多家医疗公司咨询开发创新产品，借鉴了他在临床试验方面的长期经验。
- Neil Ghodadra has served as Chief Medical Officer and a director since October 2018. Since July 2011, Dr. Ghodadra has served as the President of Neil Ghodadra MD Inc. Dr. Ghodadra is a board certified orthopedic surgeon specializing in minimally invasive, arthroscopic surgeries of the knee, shoulder, elbow and hip. He possesses extensive expertise in cartilage restoration and joint preserving osteotomies, focusing on complex shoulder conditions such as instability and rotator cuff repairs. Dr. Ghodadra holds a Bachelor of Science from Duke University and a Doctor of Medicine from Duke University. Dr. Ghodadra completed his residency at Rush Medical Center in Chicago and a Sports Medicine Fellowship, during which he served as an associate team physician for the Chicago Bulls and Chicago White Sox. Beyond his clinical practice, he consults with multiple medical companies to develop innovative products, drawing on his lengthy experience in clinical trials.
- Kent Kester
-
Kent Kester目前是一名董事提名人，并将在该前景构成部分的登记声明生效后作为独立董事加入董事会。自1997年以来，凯斯特博士一直担任巴尔的摩马里兰大学休克创伤中心的活跃临床医生。自2024年8月以来，他还在CEPI（疫情防备创新联盟）领导疫苗研发工作。Kester博士拥有巴克内尔大学生物学理学学士学位和杰斐逊医学院医学博士学位。
Kent Kester has served as a director since September 2025. Since 1997, Dr. Kester has served as an active clinician at the University of Maryland Shock Trauma Center in Baltimore. He has also led vaccine research and development at CEPI, the Coalition for Epidemic Preparedness Innovations, since August 2024. Dr. Kester holds a Bachelor of Science in Biology from Bucknell University and an M.D. from Jefferson Medical College. - Kent Kester目前是一名董事提名人，并将在该前景构成部分的登记声明生效后作为独立董事加入董事会。自1997年以来，凯斯特博士一直担任巴尔的摩马里兰大学休克创伤中心的活跃临床医生。自2024年8月以来，他还在CEPI（疫情防备创新联盟）领导疫苗研发工作。Kester博士拥有巴克内尔大学生物学理学学士学位和杰斐逊医学院医学博士学位。
- Kent Kester has served as a director since September 2025. Since 1997, Dr. Kester has served as an active clinician at the University of Maryland Shock Trauma Center in Baltimore. He has also led vaccine research and development at CEPI, the Coalition for Epidemic Preparedness Innovations, since August 2024. Dr. Kester holds a Bachelor of Science in Biology from Bucknell University and an M.D. from Jefferson Medical College.
- Arthur Golden
-
Arthur Golden目前是董事提名人，并将在该前景构成部分的登记声明生效后作为独立董事加入董事会。自2020年1月起，Golden先生担任Davis Polk & Wardll LLP的高级法律顾问。在担任该职务之前，Golden先生是Davis Polk并购业务的全球联席主席。他在代表公司处理收购相关交易以及就公司治理、股东积极性和防御事项向客户提供建议方面拥有丰富的经验。2000年至2024年，Golden先生在艾默生电气董事会任职。Golden先生目前担任Rensselaer Polytechnic Institute（“RPI”）的名誉主席。Golden先生拥有RPI的数学理学学士学位和纽约大学法学院的法学博士学位。
Arthur Golden has served as a director since September 2025. Since January 2020, Mr. Golden has served as Senior Counsel at Davis Polk & Wardwell LLP ("Davis Polk"). Prior to that role, Mr. Golden was the global co chairman of Davis Polk's Mergers and Acquisitions practice. He has extensive experience representing companies with respect to acquisition related transactions and advising clients on corporate governance, stockholder activism, and defensive matters. From 2000 to 2024, Mr. Golden served on the board of directors of Emerson Electric. Mr. Golden currently serves as Chairman Emeritus at Rensselaer Polytechnic Institute ("RPI"). Mr. Golden holds a Bachelor of Science in Mathematics from RPI and a J.D. from New York University School of Law. - Arthur Golden目前是董事提名人，并将在该前景构成部分的登记声明生效后作为独立董事加入董事会。自2020年1月起，Golden先生担任Davis Polk & Wardll LLP的高级法律顾问。在担任该职务之前，Golden先生是Davis Polk并购业务的全球联席主席。他在代表公司处理收购相关交易以及就公司治理、股东积极性和防御事项向客户提供建议方面拥有丰富的经验。2000年至2024年，Golden先生在艾默生电气董事会任职。Golden先生目前担任Rensselaer Polytechnic Institute（“RPI”）的名誉主席。Golden先生拥有RPI的数学理学学士学位和纽约大学法学院的法学博士学位。
- Arthur Golden has served as a director since September 2025. Since January 2020, Mr. Golden has served as Senior Counsel at Davis Polk & Wardwell LLP ("Davis Polk"). Prior to that role, Mr. Golden was the global co chairman of Davis Polk's Mergers and Acquisitions practice. He has extensive experience representing companies with respect to acquisition related transactions and advising clients on corporate governance, stockholder activism, and defensive matters. From 2000 to 2024, Mr. Golden served on the board of directors of Emerson Electric. Mr. Golden currently serves as Chairman Emeritus at Rensselaer Polytechnic Institute ("RPI"). Mr. Golden holds a Bachelor of Science in Mathematics from RPI and a J.D. from New York University School of Law.
- Martin Dewhurst
-
Martin Dewhurst，自2024年7月起担任GHO Capital的顾问，该公司是一家医疗保健专业私募股权投资公司。Dewhurst先生自2023年4月起担任全球投资和并购咨询银行PJT Partners的高级顾问。自2023年4月以来，杜赫斯特先生还担任成长型资本基金LightRock的高级顾问。Dewhurst先生还担任多个董事会职务，包括在Unilabs Ltd.（自2025年9月起）、KOS AI（自2025年6月起）、Cytovation ASA（自2025年2月起）、Distalmotion（自2023年4月起）和MedGenome（自2023年4月至2025年1月）。在担任各种顾问和董事会职务之前，Dewhurst先生是麦肯锡公司的高级合伙人，麦肯锡公司是一家领先的管理咨询公司，他从1992年到2023年在该公司任职，并共同领导了该公司的生命科学实践（2014年至2021年）。Dewhurst先生在牛津大学Magdalen学院获得本科学位，并拥有欧洲工商管理学院的MBA学位，并在该学院的院长名单上毕业。
Martin Dewhurst has served as a director since January 2026. Mr. Dewhurst has served as advisor to GHO Capital, a healthcare specialist private equity firm, since July 2024. Mr. Dewhurst has been a senior advisor since April 2023 to PJT Partners, a global investment and M&A advisory bank. Mr. Dewhurst has also served as a senior advisor to LightRock, a growth capital fund, since April 2023. Mr. Dewhurst also holds various board positions including at Unilabs Ltd. (since September 2025), KOS AI (since June 2025), Cytovation ASA (since February 2025), Distalmotion (since April 2023) and MedGenome (April 2023 through January 2025). Prior to his various advisory and board roles, Mr. Dewhurst was a senior partner with McKinsey & Company, a leading management consulting firm where he served from 1992 through 2023 and co led the firm's life sciences practice (2014 to 2021). Mr. Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD, where he graduated on the Dean's List. - Martin Dewhurst，自2024年7月起担任GHO Capital的顾问，该公司是一家医疗保健专业私募股权投资公司。Dewhurst先生自2023年4月起担任全球投资和并购咨询银行PJT Partners的高级顾问。自2023年4月以来，杜赫斯特先生还担任成长型资本基金LightRock的高级顾问。Dewhurst先生还担任多个董事会职务，包括在Unilabs Ltd.（自2025年9月起）、KOS AI（自2025年6月起）、Cytovation ASA（自2025年2月起）、Distalmotion（自2023年4月起）和MedGenome（自2023年4月至2025年1月）。在担任各种顾问和董事会职务之前，Dewhurst先生是麦肯锡公司的高级合伙人，麦肯锡公司是一家领先的管理咨询公司，他从1992年到2023年在该公司任职，并共同领导了该公司的生命科学实践（2014年至2021年）。Dewhurst先生在牛津大学Magdalen学院获得本科学位，并拥有欧洲工商管理学院的MBA学位，并在该学院的院长名单上毕业。
- Martin Dewhurst has served as a director since January 2026. Mr. Dewhurst has served as advisor to GHO Capital, a healthcare specialist private equity firm, since July 2024. Mr. Dewhurst has been a senior advisor since April 2023 to PJT Partners, a global investment and M&A advisory bank. Mr. Dewhurst has also served as a senior advisor to LightRock, a growth capital fund, since April 2023. Mr. Dewhurst also holds various board positions including at Unilabs Ltd. (since September 2025), KOS AI (since June 2025), Cytovation ASA (since February 2025), Distalmotion (since April 2023) and MedGenome (April 2023 through January 2025). Prior to his various advisory and board roles, Mr. Dewhurst was a senior partner with McKinsey & Company, a leading management consulting firm where he served from 1992 through 2023 and co led the firm's life sciences practice (2014 to 2021). Mr. Dewhurst earned his undergraduate degree from Magdalen College, University of Oxford, and holds an MBA from INSEAD, where he graduated on the Dean's List.
高管简历
中英对照 | 中文 | 英文- Zuraiz Chaudhary
Zuraiz Chaudhary自AugGlobal Health Solutions，Inc.t 2025起担任Global Health Solutions，Inc.临时首席财务官；自2025年5月起担任Global Health Solutions，Inc.财务副总裁兼首席会计官。Chaudhary先生拥有十年的公共会计和咨询服务背景，是一名持牌注册会计师。从2024年3月至2025年3月，Chaudhary先生担任公共会计师事务所SetApart的审计总监。2023年6月至2024年3月，Chaudhary先生担任公共会计师事务所UHY LLP的审计经理。在加入UHY LLP之前，从2021年9月到2023年3月，Chaudhary先生是bGlobal Health Solutions，Inc.iness咨询公司CrossCountry Consulting的高级顾问。从2020年6月到AugGlobal Health Solutions，Inc.t 2021，他在bGlobal Health Solutions，Inc.iness咨询公司BlackStone Consultants担任董事总经理。Chaudhary先生拥有马来西亚亚欧大学BGlobal Health Solutions，Inc.iness Administration（Accounting）学士学位，自2021年起成为巴基斯坦特许会计师协会成员。
Zuraiz Chaudhary has served as Interim Chief Financial Officer since August 2025 and Vice President of Finance and Chief Accounting Officer since May 2025. Mr. Chaudhary has a decade of public accounting and advisory services background and is a licensed CPA. From March 2024 to March 2025, Mr. Chaudhary was an Audit Director at SetApart Accountancy Corp, a public accounting firm. From June 2023 to March 2024, Mr. Chaudhary served as an Audit Manager of UHY LLP, a public accounting firm. Prior to joining UHY LLP, from September 2021 to March 2023, Mr. Chaudhary was a Senior Consultant at CrossCountry Consulting, a business advisory firm. From June 2020 to August 2021, he served as Managing Director at BlackStone Consultants, a business advisory firm. Prior to that, he served in various roles at PwC and KPMG. Mr. Chaudhary has a Bachelor of Business Administration (Accounting) from Asia e University, Malaysia and has been a member of the Institute of Chartered Accountants of Pakistan since 2021.- Zuraiz Chaudhary自AugGlobal Health Solutions，Inc.t 2025起担任Global Health Solutions，Inc.临时首席财务官；自2025年5月起担任Global Health Solutions，Inc.财务副总裁兼首席会计官。Chaudhary先生拥有十年的公共会计和咨询服务背景，是一名持牌注册会计师。从2024年3月至2025年3月，Chaudhary先生担任公共会计师事务所SetApart的审计总监。2023年6月至2024年3月，Chaudhary先生担任公共会计师事务所UHY LLP的审计经理。在加入UHY LLP之前，从2021年9月到2023年3月，Chaudhary先生是bGlobal Health Solutions，Inc.iness咨询公司CrossCountry Consulting的高级顾问。从2020年6月到AugGlobal Health Solutions，Inc.t 2021，他在bGlobal Health Solutions，Inc.iness咨询公司BlackStone Consultants担任董事总经理。Chaudhary先生拥有马来西亚亚欧大学BGlobal Health Solutions，Inc.iness Administration（Accounting）学士学位，自2021年起成为巴基斯坦特许会计师协会成员。
- Zuraiz Chaudhary has served as Interim Chief Financial Officer since August 2025 and Vice President of Finance and Chief Accounting Officer since May 2025. Mr. Chaudhary has a decade of public accounting and advisory services background and is a licensed CPA. From March 2024 to March 2025, Mr. Chaudhary was an Audit Director at SetApart Accountancy Corp, a public accounting firm. From June 2023 to March 2024, Mr. Chaudhary served as an Audit Manager of UHY LLP, a public accounting firm. Prior to joining UHY LLP, from September 2021 to March 2023, Mr. Chaudhary was a Senior Consultant at CrossCountry Consulting, a business advisory firm. From June 2020 to August 2021, he served as Managing Director at BlackStone Consultants, a business advisory firm. Prior to that, he served in various roles at PwC and KPMG. Mr. Chaudhary has a Bachelor of Business Administration (Accounting) from Asia e University, Malaysia and has been a member of the Institute of Chartered Accountants of Pakistan since 2021.
- Bradley Burnam
Bradley Burnam自2018年10月起担任Global Health Solutions，Inc.首席执行官和董事。Burnam先生是一位创新者和企业家，在开发突破性的医疗保健解决方案方面有着良好的业绩记录。Burnam先生推动了变革性医疗产品的开发，并获得了三项FDA许可。他拥有10多项已发布的专利，体现了他在配方和创新方面的专长。他深厚的监管知识让alloGlobal Health Solutions，Inc.让他以顾问的身份独立驾驭FDA的批准流程。Burnam先生自2020年12月起担任Baropace，LLC的董事。Burnam先生拥有加州大学洛杉矶分校（“UCLA”）的文学学士学位和斯坦福大学的教育硕士学位。
Bradley Burnam has served as Chief Executive Officer and as a director since October 2018. Mr. Burnam is an innovator and entrepreneur with a proven track record in developing groundbreaking healthcare solutions. Mr. Burnam has driven the development of transformative medical products and achieved three FDA clearances. He holds over 10 issued patents, reflecting his expertise in formulation and innovation. His deep regulatory knowledge has allowed him to navigate FDA approval processes independently and as a consultant. Mr. Burnam has served as a director of Baropace, LLC since December 2020. Mr. Burnam holds a Bachelor of Arts from the University of California, Los Angeles ("UCLA") and a Master of Education from Stanford University.- Bradley Burnam自2018年10月起担任Global Health Solutions，Inc.首席执行官和董事。Burnam先生是一位创新者和企业家，在开发突破性的医疗保健解决方案方面有着良好的业绩记录。Burnam先生推动了变革性医疗产品的开发，并获得了三项FDA许可。他拥有10多项已发布的专利，体现了他在配方和创新方面的专长。他深厚的监管知识让alloGlobal Health Solutions，Inc.让他以顾问的身份独立驾驭FDA的批准流程。Burnam先生自2020年12月起担任Baropace，LLC的董事。Burnam先生拥有加州大学洛杉矶分校（“UCLA”）的文学学士学位和斯坦福大学的教育硕士学位。
- Bradley Burnam has served as Chief Executive Officer and as a director since October 2018. Mr. Burnam is an innovator and entrepreneur with a proven track record in developing groundbreaking healthcare solutions. Mr. Burnam has driven the development of transformative medical products and achieved three FDA clearances. He holds over 10 issued patents, reflecting his expertise in formulation and innovation. His deep regulatory knowledge has allowed him to navigate FDA approval processes independently and as a consultant. Mr. Burnam has served as a director of Baropace, LLC since December 2020. Mr. Burnam holds a Bachelor of Arts from the University of California, Los Angeles ("UCLA") and a Master of Education from Stanford University.
- Neil Ghodadra
Neilesh“Neil”Shailesh Ghodadra博士自2018年10月起担任Global Health Solutions，Inc.首席医疗官和董事。自2011年7月以来，Ghodadra博士一直担任Neil Ghodadra MD Inc.的总裁。Ghodadra博士是一名获得董事会认证的骨科外科医生，专门从事膝关节、肩关节、肘关节和髋关节的微创、关节镜手术。他在软骨修复和关节保持性截骨方面拥有广泛的专业知识，专注于不稳定和肩袖修复等复杂肩部疾病。Ghodadra博士拥有杜克大学的理学学士学位和杜克大学的医学博士学位。Ghodadra博士完成了在芝加哥RGlobal Health Solutions，Inc.h医疗中心的住院治疗，并获得了运动医学奖学金，在此期间，他曾担任芝加哥公牛和芝加哥白袜的副队医生。除了临床实践，他还向多家医疗公司咨询开发创新产品，借鉴了他在临床试验方面的长期经验。
Neil Ghodadra has served as Chief Medical Officer and a director since October 2018. Since July 2011, Dr. Ghodadra has served as the President of Neil Ghodadra MD Inc. Dr. Ghodadra is a board certified orthopedic surgeon specializing in minimally invasive, arthroscopic surgeries of the knee, shoulder, elbow and hip. He possesses extensive expertise in cartilage restoration and joint preserving osteotomies, focusing on complex shoulder conditions such as instability and rotator cuff repairs. Dr. Ghodadra holds a Bachelor of Science from Duke University and a Doctor of Medicine from Duke University. Dr. Ghodadra completed his residency at Rush Medical Center in Chicago and a Sports Medicine Fellowship, during which he served as an associate team physician for the Chicago Bulls and Chicago White Sox. Beyond his clinical practice, he consults with multiple medical companies to develop innovative products, drawing on his lengthy experience in clinical trials.- Neilesh“Neil”Shailesh Ghodadra博士自2018年10月起担任Global Health Solutions，Inc.首席医疗官和董事。自2011年7月以来，Ghodadra博士一直担任Neil Ghodadra MD Inc.的总裁。Ghodadra博士是一名获得董事会认证的骨科外科医生，专门从事膝关节、肩关节、肘关节和髋关节的微创、关节镜手术。他在软骨修复和关节保持性截骨方面拥有广泛的专业知识，专注于不稳定和肩袖修复等复杂肩部疾病。Ghodadra博士拥有杜克大学的理学学士学位和杜克大学的医学博士学位。Ghodadra博士完成了在芝加哥RGlobal Health Solutions，Inc.h医疗中心的住院治疗，并获得了运动医学奖学金，在此期间，他曾担任芝加哥公牛和芝加哥白袜的副队医生。除了临床实践，他还向多家医疗公司咨询开发创新产品，借鉴了他在临床试验方面的长期经验。
- Neil Ghodadra has served as Chief Medical Officer and a director since October 2018. Since July 2011, Dr. Ghodadra has served as the President of Neil Ghodadra MD Inc. Dr. Ghodadra is a board certified orthopedic surgeon specializing in minimally invasive, arthroscopic surgeries of the knee, shoulder, elbow and hip. He possesses extensive expertise in cartilage restoration and joint preserving osteotomies, focusing on complex shoulder conditions such as instability and rotator cuff repairs. Dr. Ghodadra holds a Bachelor of Science from Duke University and a Doctor of Medicine from Duke University. Dr. Ghodadra completed his residency at Rush Medical Center in Chicago and a Sports Medicine Fellowship, during which he served as an associate team physician for the Chicago Bulls and Chicago White Sox. Beyond his clinical practice, he consults with multiple medical companies to develop innovative products, drawing on his lengthy experience in clinical trials.